Count on us for updates on the coronavirus and guidance for cancer patients and family members.Read the latest articles
Dr. Lecia Sequist is the Associate Professor of Medicine at Harvard Medical School and the Mary B. Saltonstall Endowed Chair in Oncology at the Massachusetts General Hospital Cancer Center (MGH). Her research is focused on the study of novel targets and targeted agents for lung cancer treatment, particularly those that target the epidermal growth factor receptor (EGFR) and circulating tumor cells (CTCs). She hopes to develop more personalized therapies based on the patient’s cancer genotypes. Dr. Sequist studied chemistry at Cornell University and received her medical doctorate from Harvard Medical School. She practiced internal medicine at the Brigham and Women's Hospital and hematology/oncology at the DFCI/MGH joint program, where she also received an MPH from the Harvard School of Public Health. In 2005, she became a faculty member at the Center for Thoracic Cancers at the Massachusetts General Hospital Cancer Center. She has an active clinical and translational research career, as well as a busy practice caring for patients with lung cancer.